Any current/future new fundraising through debt or equity?

The company has committed capex of around INR 55 to 58 crores for various expansions in FY '25. If volumes grow in pharma, additional growth investment might be required in the second half of the year. Overall capex for FY '25 is expected to be around INR 75 to 80 crores, compared to INR 140 crores last year. No direct mention or indication of new fundraising through debt or equity was made in the transcript. Focus seems to be on utilizing internal accruals and existing resources for capacity expansion and ramp-up.

Any current/future capex/capital investment/strategic investment?

Current committed capex for FY '25 is around INR 55 to 58 crores for various expansions. Additional growth investment in pharma may raise total capex to INR 75 to 80 crores by year-end. Capacity expansions include increasing ABG plants' capacity by 60% to 75% at Cheyyur and Mahad. Mahad plant will start supply from September/October, adding to volume growth. Pharma plant capacity may be enhanced with auxiliary machines within 3-4 months if needed. Capex in FY '25 is lower than last year's INR 140 crores. The company aims to double ABG capacities and expand pharmaceutical capacity to boost grow

Future growth expectations in sales/revenue/volumes?

Volume growth guidance for FY '25 is around 15%, with a higher run rate of 17% needed in the remaining 9 months due to a moderate Q1 growth of 7.5%. Pharma segment is expected to grow significantly, contributing around INR15-20 crores in FY '25 with higher EBITDA, and potentially pushing turnover to INR50-60 crores by FY '26. Qpacks are growing rapidly, with expectations of 40-50% volume growth in the Food & FMCG segment. ABG segment capacity expansions (especially Cheyyar and Mahad plants) will add over 1,000 tons/month volume, supporting growth. Paints sector growth is expected aroun

Future growth expectations in earnings/operating earnings/profits/EPS?

The company targets overall volume growth of around 15% for FY '25, with a high run rate needed in last 3 quarters. Pharma segment expected to significantly contribute from Q3 FY '25, with turnover potential of INR50-60 crores by FY '26, and handsome EBITDA of INR100-150 per kg depending on product mix. EBITDA per kg target is 40 by end of FY '25, up from 37.1 in Q1 FY '25, driven by pharma contribution and ramp-up in ABG capacities. Capex for FY '25 is estimated at INR75-80 crores (vs INR140 crores last year) aimed at capacity expansion for ABG and pharma. Revenue could approach INR1,

Current/ Expected Orderbook/ Pending Orders?

The company is witnessing strong indications for volume ramp-up, especially from pharma and ABG plants starting Q2 and Q3. For pharma, orders are developing rapidly with 4 major clients auditing and approving the company as a vendor; several products are in final development stages. Expected pharma sales: INR 80 lakhs in Q1, INR 2-2.5 crores in Q2, and INR 5-6 crores in Q3 and Q4, totaling INR 15-20 crores for the year. ABG paints plant (including Mahad starting September/October) expected to add more than 1,000 tons per month in volumes. Expansion efforts are ongoing with loading expected by

IN US

Sale is live|00:00:00left today

Mold-Tek Packaging LtdQ2 FY24Industrial Products

Mold-Tek Packaging Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹702P/E: 32.3Market Cap: ₹2.3K CrSector: Industrial Products

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Volume growth guidance for FY '25 is around 15%, with a higher run rate of 17% needed in the remaining 9 months due to a moderate Q1 growth of 7.5%.
→Pharma segment is expected to grow significantly, contributing around INR15-20 crores in FY '25 with higher EBITDA, and potentially pushing turnover to INR50-60 crores by FY '26.
→Qpacks are growing rapidly, with expectations of 40-50% volume growth in the Food & FMCG segment.
→ABG segment capacity expansions (especially Cheyyar and Mahad plants) will add over 1,000 tons/month volume, supporting growth.
→Paints sector growth is expected around 8-10%, driven by ABG and other clients.
→Overall volumes grew by 7.5% in Q1 with a recent trend showing improvement, targeting continued growth from Q3 onward.
→The company aims to reach INR1,000 crores top line and INR100 crores PAT by FY '26/'27 largely driven by pharma and ABG expansions.

Margin guidance

Category 3

→The company targets overall volume growth of around 15% for FY '25, with a high run rate needed in last 3 quarters.
→Pharma segment expected to significantly contribute from Q3 FY '25, with turnover potential of INR50-60 crores by FY '26, and handsome EBITDA of INR100-150 per kg depending on product mix.
→EBITDA per kg target is 40 by end of FY '25, up from 37.1 in Q1 FY '25, driven by pharma contribution and ramp-up in ABG capacities.
→Capex for FY '25 is estimated at INR75-80 crores (vs INR140 crores last year) aimed at capacity expansion for ABG and pharma.
→Revenue could approach INR1,000 crores in FY '25/'26, with PAT potentially crossing INR100 crores if pharma growth materializes well by FY '26/'27.
→Increased capacity utilization expected from Q3 onwards in pharma and ABG plants will drive improved earnings.

3 more insights locked — sign up free to unlock

Fundraise plans

→The company has committed capex of around INR 55 to 58 crores for various expansions in FY '25.
→If volumes grow in pharma, additional growth investment might be required in the second half of the year.
→Overall capex for FY '25 is expected to be around INR 75 to 80 crores, compared to INR 140 crores last year.
→No direct mention or indication of new fundraising through debt or equity was made in the transcript.
→Focus seems to be on utilizing internal accruals and existing resources for capacity expansion and ramp-up.

Order book

→The company is witnessing strong indications for volume ramp-up, especially from pharma and ABG plants starting Q2 and Q3.
→For pharma, orders are developing rapidly with 4 major clients auditing and approving the company as a vendor; several products are in final development stages.
→Expected pharma sales: INR 80 lakhs in Q1, INR 2-2.5 crores in Q2, and INR 5-6 crores in Q3 and Q4, totaling INR 15-20 crores for the year.
→ABG paints plant (including Mahad starting September/October) expected to add more than 1,000 tons per month in volumes.
→Expansion efforts are ongoing with loading expected by December for new volumes, aiming to double capacity, particularly in North India.
→Overall volume guidance remains mid-teens (around 15%) growth for FY '25, supported by pharma and ABG orderbooks.
→Utilization at ABG plants currently around 40-45%, expected to reach 50-60% in the full year.

Capex plans

Yes

→Current committed capex for FY '25 is around INR 55 to 58 crores for various expansions.
→Additional growth investment in pharma may raise total capex to INR 75 to 80 crores by year-end.
→Capacity expansions include increasing ABG plants' capacity by 60% to 75% at Cheyyur and Mahad.
→Mahad plant will start supply from September/October, adding to volume growth.
→Pharma plant capacity may be enhanced with auxiliary machines within 3-4 months if needed.
→Capex in FY '25 is lower than last year's INR 140 crores.
→The company aims to double ABG capacities and expand pharmaceutical capacity to boost growth.

How does Mold-Tek Packaging Ltd rank vs peers in Industrial Products?

Pro feature

1Mold-Tek Packaging Ltd

Rev 3Mar 3

See full Industrial Products sector rankings

Want more stocks like Mold-Tek Packaging Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio